We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Navidea Biopharmaceuticals Inc (NAVB) USD0.001

Sell:$1.22 Buy:$1.35 Change: No change
Market closed |  Prices as at close on 24 November 2021 | Switch to live prices |
Sell:$1.22
Buy:$1.35
Change: No change
Market closed |  Prices as at close on 24 November 2021 | Switch to live prices |
Sell:$1.22
Buy:$1.35
Change: No change
Market closed |  Prices as at close on 24 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Navidea Biopharmaceuticals, Inc. (Navidea) is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company focuses on two drug product diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694, and therapeutic development programs, including therapeutic applications of Manocept platform. It also focuses on developing multiple precision-targeted products based on Manocept platform by identifying the sites and pathways of undetected disease and provide diagnostic services. Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the product developed and commercialized by Navidea based on the platform.

Contact details

Address:
4995 Bradenton Ave Ste 240
DUBLIN
43017-3552
United States
Telephone:
+1 (614) 7937500
Website:
https://www.navidea.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NAVB
ISIN:
US63937X2027
Market cap:
$39.25 million
Shares in issue:
30.19 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Alexander Cappello
    Chairman of the Board
  • John Scott
    Vice Chairman of the Board
  • Michel Mikhail
    Chief Regulatory Officer
  • Michael Rosol
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.